Physician profile
Marc R Mitchell
NPI 1588687354
$1,375.60
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,223 · 2020: $153.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $210.28 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $209.23 | 2019 | |
| Janssen Pharmaceuticals, INC | $199.57 | 2019-2020 | |
| Pfizer INC. | $165.07 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $79.06 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $77.77 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $67.67 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $63.17 | 2019-2020 | |
| Horizon Therapeutics Plc | $54.02 | 2019 | |
| Astellas Pharma US INC | $44.52 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $36.10 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $33.74 | 2019 | |
| Glaxosmithkline, LLC. | $31.94 | 2019 | |
| Amarin Pharma, INC. | $19.24 | 2019 | |
| Novo Nordisk INC | $18.80 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $18.53 | 2019 | |
| Dynavax Technologies Corporation | $17.10 | 2019 | |
| Boston Scientific Corporation | $16.66 | 2019 | |
| Avanir Pharmaceuticals, INC. | $13.13 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Mitchell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.